7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one
• 英文别名: 7-hydroxy-3-(4-iodophenoxy)chromen-4-one
• 化学式: C₁₅H₉IO₄
• mdl: MFCD00525548
• 分子量: 380.13
• InChiKey: XXZKJJYWINSUMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
  申请人：Pragma Therapeutics

  公开号：EP3459939A1

  公开（公告）日：2019-03-27

  The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 ("mGluR7"). The present invention also relates to pharmaceutical composition comprising such compound and their use for the treatment of prevention of disorders associated with glutamate dysfunction.

  本发明涉及新颖的杂环化合物。该发明还涉及调节代谢型谷氨酸受体（mGluR）的化合物，优选是代谢型谷氨酸受体亚型7（"mGluR7"）。本发明还涉及包含这种化合物的药物组合物及其用于治疗或预防与谷氨酸功能障碍相关的疾病的用途。
• HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
  申请人：PRAGMA Therapeutics

  公开号：US20220363664A1

  公开（公告）日：2022-11-17

  The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 (“mGluR7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably mGluR7 subtype of metabotropic glutamate receptors, is involved.
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7<br/>[FR] NOUVEAUX COMPOSES HÉTÉROCYCLIQUES UTILISÉS EN TANT QUE MODULATEURS DE MGLUR7
  申请人：PRAGMA THERAPEUTICS

  公开号：WO2019063596A1

  公开（公告）日：2019-04-04

  The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (m Glu R), preferably of the metabotropic glutamate receptor subtype 7 ("m Glu R7"). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably m Glu R7 subtype of metabotropic glutamate receptors, is involved.